CCA
LJPC

Catalyst Capital Advisors’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Catalyst Capital Advisors’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-45,000
Closed -$1.22M – 703
2015
Q4 		$1.22M Hold
45,000
– – 0.18% 114
2015
Q3 		$1.25M Hold
45,000
– – 0.17% 128
2015
Q2 		$1.1M Buy
+45,000
New +$927K 0.13% 154

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Catalyst Capital Advisors's LJPC Position: Q1 2016 in Review

Catalyst Capital Advisors sold out of La Jolla Pharmaceutical Company (LJPC) in Q1 2016, closing a stake of 45,000 shares — an estimated $1.22M sold.

Catalyst Capital Advisors first reported a position in LJPC in Q2 2015 and held it in 3 quarters. The position peaked at $1.25M in Q3 2015. 70 funds tracked by Wall St. Rank hold LJPC as of Q1 2016.

  • Catalyst Capital Advisors reported no remaining La Jolla Pharmaceutical Company position as of Q1 2016 after selling out during the quarter.
  • Catalyst Capital Advisors sold 45,000 La Jolla Pharmaceutical Company shares in Q1 2016, an estimated $1.22M.
  • Catalyst Capital Advisors first reported a position in La Jolla Pharmaceutical Company in Q2 2015 and held it in 3 quarters.
  • Catalyst Capital Advisors's La Jolla Pharmaceutical Company position peaked at $1.25M in Q3 2015.
  • 70 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q1 2016.

Based on Catalyst Capital Advisors's 13F filing for Q1 2016, filed 11 May 2016.